Literature DB >> 28176416

Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry.

Lars H Lund1,2, Frieder Braunschweig1,2, Lina Benson3, Marcus Ståhlberg1,2, Ulf Dahlström4, Cecilia Linde1,2.   

Abstract

AIMS: Cardiac resynchronization therapy (CRT) improves outcomes in heart failure (HF) but may be underutilized. The reasons are unknown. METHODS AND
RESULTS: We linked the Swedish Heart Failure Registry to national registries with ICD-10 (International Classification of Diseases-10th Revision) co-morbidity diagnoses and demographic and socio-economic data. In patients with EF ≤39% and NYHA II-IV, we assessed prevalence of CRT indication and CRT use. In those with CRT indication, we assessed the association between 37 potential baseline covariates and CRT non-use using multivariable generalized estimating equation (GEE) models. Of 12 807 patients (mean age 71 ± 12 years, 28% female), 841 (7%) had CRT, 3094 (24%) had an indication for but non-use of CRT, and 8872 (69%) had no indication. Important variables independently associated with CRT non-use were: HF duration <6 months [risk ratio (RR) 1.21, 95% confidence interval (CI) 1.17-1.24]; non-cardiology planned follow-up (RR 1.14, 95% CI 1.09-1.18); age >75 years (RR 1.13, 95% CI 1.09-1.18); non-cardiology care at baseline (RR 1.10, 95% CI 1.07-1.14); small-town non-university centre (RR 1.08, 95% CI 1.05-1.12); female sex (RR 1.07 95% CI 1.03-1.10) (all P < 0.05); as was absence of AF, living alone; psychiatric diagnosis; smoking; and non-use of HF drugs. Education, income, cancer, or HF characteristics were not independently associated with CRT non-use.
CONCLUSION: In this population-wide HF registry, CRT was underutilized. Non-use was associated mostly with demographic and organizational, but not clinical or socio-economic factors. This calls for programmes to raise awareness of CRT indications and improve access and referrals to cardiology specialists.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Cardiac resynchronization therapy; Epidemiology; Guidelines; Heart failure; Implementation; Utilization

Mesh:

Year:  2017        PMID: 28176416     DOI: 10.1002/ejhf.781

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  15 in total

1.  A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure.

Authors:  Erik Nilsson; Pietro De Deco; Marco Trevisan; Rino Bellocco; Bengt Lindholm; Lars H Lund; Josef Coresh; Juan J Carrero
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-10-01

2.  Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials.

Authors:  Michael E Nassif; Yuanyuan Tang; John G Cleland; William T Abraham; Cecilia Linde; Michael R Gold; James B Young; J Claude Daubert; Lou Sherfesee; Dan Schaber; Anthony S L Tang; Philip G Jones; Suzanne V Arnold; John A Spertus
Journal:  Circ Heart Fail       Date:  2017-10       Impact factor: 8.790

Review 3.  The Canadian Women's Heart Health Alliance Atlas on the Epidemiology, Diagnosis, and Management of Cardiovascular Disease in Women - Chapter 6: Sex- and Gender-Specific Diagnosis and Treatment.

Authors:  Monica Parry; Harriette G C Van Spall; Kerri-Anne Mullen; Sharon L Mulvagh; Christine Pacheco; Tracey J F Colella; Marie-Annick Clavel; Shahin Jaffer; Heather J A Foulds; Jasmine Grewal; Marsha Hardy; Jennifer A D Price; Anna L E Levinsson; Christine A Gonsalves; Colleen M Norris
Journal:  CJC Open       Date:  2022-04-19

4.  Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization.

Authors:  Gianluigi Savarese; Lars H Lund; Ulf Dahlström; Anna Strömberg
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

5.  Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry.

Authors:  Uwe Zeymer; Andrew L Clark; Vivencio Barrios; Thibaud Damy; Jaroslaw Drożdż; Candida Fonseca; Lars H Lund; Gabriele Di Comite; Stephan Hupfer; Aldo P Maggioni
Journal:  ESC Heart Fail       Date:  2020-02-06

Review 6.  Highlights in heart failure.

Authors:  Daniela Tomasoni; Marianna Adamo; Carlo Mario Lombardi; Marco Metra
Journal:  ESC Heart Fail       Date:  2019-12

7.  Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock.

Authors:  Benedikt Schrage; Peter Moritz Becher; Alina Goßling; Gianluigi Savarese; Salim Dabboura; Isabell Yan; Benedikt Beer; Gerold Söffker; Moritz Seiffert; Stefan Kluge; Paulus Kirchhof; Stefan Blankenberg; Dirk Westermann
Journal:  ESC Heart Fail       Date:  2021-02-19

8.  Sex-Specific Patterns of Mortality Predictors Among Patients Undergoing Cardiac Resynchronization Therapy: A Machine Learning Approach.

Authors:  Márton Tokodi; Anett Behon; Eperke Dóra Merkel; Attila Kovács; Zoltán Tősér; András Sárkány; Máté Csákvári; Bálint Károly Lakatos; Walter Richard Schwertner; Annamária Kosztin; Béla Merkely
Journal:  Front Cardiovasc Med       Date:  2021-02-25

9.  Utilization of cardiac resynchronization therapy in patients with heart failure in the Northern Region of New Zealand.

Authors:  Khang-Li Looi; Andrew Gavin; Karishma Sidhu; Lisa Cooper; Liane Dawson; Debbie Slipper; Nigel Lever
Journal:  J Arrhythm       Date:  2018-11-02

10.  Impact of Guidelines on the Diffusion of Medical Technology: A Case Study of Cardiac Resynchronization Therapy in the UK.

Authors:  Rucha Vadia; Tom Stargardt
Journal:  Appl Health Econ Health Policy       Date:  2020-09-24       Impact factor: 2.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.